NerPharMa - Part of NMS Group

NerPharMa Team thanks all customers, business partners and friends visiting us at our booth at CPHI Milano. A very successful week promoting our fully integrated solutions for High Potent Drug Development and commercialization: from drug substance, drug product (injectables as solutions, lipolyzed, bags, oral tables and capsules) to secondary packaging and distribution. Looking forward to showcase again at CPHI Frankfurt 2025 and other events next year!

NerPharMa Team thanks all customers, business partners and friends visiting us at our booth at CPHI Milano. A very successful week promoting our fully integrated solutions for High Potent Drug Development and commercialization: from drug substance, drug product (injectables as solutions, lipolyzed, bags, oral tables and capsules) to secondary packaging and distribution. Looking forward to showcase again at CPHI Frankfurt 2025 and other events next year!

Last Day @ CPHI Rho Fiera. Thanks to everybody!

Last Day @ CPHI Rho Fiera. Thanks to everybody!

Let’s join together CPhI Milano; a great opportunity to connect. Looking forward to meeting you at booth 18G9.

We are glad to attend CPhI as exhibitor. Looking forward to meeting you All next week at Nerpharma stand 18G9. See you soon!

𝐍𝐞𝐫𝐏𝐡𝐚𝐫𝐌𝐚 𝐀𝐩𝐩𝐨𝐢𝐧𝐭𝐬 𝐕𝐢𝐭𝐭𝐨𝐫𝐢𝐨 𝐌𝐨𝐧𝐭𝐚𝐧𝐚𝐫𝐨 𝐚𝐬 𝐍𝐞𝐰 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐚𝐥 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐒𝐢𝐭𝐞 𝐇𝐞𝐚𝐝 𝐚𝐧𝐝 𝐦𝐞𝐦𝐛𝐞𝐫 𝐨𝐟 𝐁𝐨𝐚𝐫𝐝 𝐨𝐟 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫𝐬 𝐭𝐨 𝐅𝐨𝐫𝐭𝐢𝐟𝐲 𝐨𝐮𝐫 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 𝑵𝑬𝑹𝑽𝑰𝑨𝑵𝑶, 𝑰𝑻, 𝑺𝒆𝒑𝒕𝒆𝒎𝒃𝒆𝒓 2, 2024 NerPharMa Srl (NerPharMa, part of the NMS Group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as Industrial Operation Site Head and member of the Board of Directors (Consiglio di Amministrazione). Reporting directly to Hugues Dolgos, Pharm.D., CEO of NerPharMa and NMS Group, Vittorio will spearhead efforts to uphold the highest standards of quality, safety, and compliance of NerPharMa’s diverse industrial operations, encompassing both Drug Substances and Drug Product divisions. Vittorio brings over 25 years of pharmaceutical industry experience to this role. After earning his PhD in Microbiology and Chemistry in the US, he held various senior positions at pharmaceutical sites, including R&D Director for the industrialization of new productions and Quality Unit Director at Sanofi site in Italy. Since joining NerPharMa in April 2023 as Head of Quality, Vittorio has leveraged his extensive expertise to achieve significant successes and drive quality excellence. "𝘞𝘦 𝘢𝘳𝘦 𝘵𝘩𝘳𝘪𝘭𝘭𝘦𝘥 𝘵𝘰 𝘩𝘢𝘷𝘦 𝘝𝘪𝘵𝘵𝘰𝘳𝘪𝘰 𝘢𝘴 𝘚𝘪𝘵𝘦 𝘏𝘦𝘢𝘥 𝘢𝘯𝘥 𝘮𝘦𝘮𝘣𝘦𝘳 𝘰𝘧 𝘵𝘩𝘦 𝘉𝘰𝘢𝘳𝘥 𝘰𝘧 𝘋𝘪𝘳𝘦𝘤𝘵𝘰𝘳𝘴," said Hugues Dolgos, Pharm.D., CEO of the NMS Group and CEO and Chairman of NerPharMa. "𝘏𝘪𝘴 𝘭𝘦𝘢𝘥𝘦𝘳𝘴𝘩𝘪𝘱 𝘢𝘯𝘥 𝘳𝘦𝘴𝘶𝘭𝘵𝘴-𝘥𝘳𝘪𝘷𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘦𝘷𝘪𝘥𝘦𝘯𝘵 𝘪𝘯 𝘵𝘩𝘦 𝘰𝘶𝘵𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘢𝘤𝘩𝘪𝘦𝘷𝘦𝘮𝘦𝘯𝘵𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘕𝘦𝘳𝘗𝘩𝘢𝘳𝘔𝘢 𝘘𝘶𝘢𝘭𝘪𝘵𝘺 𝘛𝘦𝘢𝘮 𝘰𝘷𝘦𝘳 𝘵𝘩𝘦 𝘱𝘢𝘴𝘵 𝘺𝘦𝘢𝘳. 𝘞𝘦 𝘢𝘳𝘦 𝘤𝘰𝘯𝘧𝘪𝘥𝘦𝘯𝘵 𝘪𝘯 𝘩𝘪𝘴 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘤𝘰𝘯𝘵𝘪𝘯𝘶𝘦 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘪𝘯𝘨 𝘦𝘹𝘤𝘦𝘱𝘵𝘪𝘰𝘯𝘢𝘭 𝘴𝘦𝘳𝘷𝘪𝘤𝘦𝘴 𝘢𝘯𝘥 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘵𝘰 𝘰𝘶𝘳 𝘤𝘭𝘪𝘦𝘯𝘵𝘴 𝘢𝘯𝘥 𝘭𝘰𝘰𝘬 𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘵𝘰 𝘩𝘪𝘴 𝘰𝘯𝘨𝘰𝘪𝘯𝘨 𝘤𝘰𝘯𝘵𝘳𝘪𝘣𝘶𝘵𝘪𝘰𝘯𝘴.” “𝘐 𝘢𝘮 𝘥𝘦𝘦𝘱𝘭𝘺 𝘩𝘰𝘯𝘰𝘳𝘦𝘥 𝘵𝘰 𝘵𝘢𝘬𝘦 𝘰𝘯 𝘵𝘩𝘦 𝘳𝘰𝘭𝘦 𝘰𝘧 𝘚𝘪𝘵𝘦 𝘏𝘦𝘢𝘥 𝘢𝘵 𝘕𝘦𝘳𝘗𝘩𝘢𝘳𝘔𝘢 𝘢𝘯𝘥 𝘵𝘳𝘶𝘭𝘺 𝘨𝘳𝘢𝘵𝘦𝘧𝘶𝘭 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘵𝘳𝘶𝘴𝘵 𝘢𝘯𝘥 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘔𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘛𝘦𝘢𝘮 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘕𝘔𝘚 𝘎𝘳𝘰𝘶𝘱 𝘉𝘰𝘢𝘳𝘥,” said Vittorio. “I 𝘸𝘪𝘭𝘭 𝘥𝘦𝘥𝘪𝘤𝘢𝘵𝘦 𝘮𝘺 𝘦𝘹𝘱𝘦𝘳𝘵𝘪𝘴𝘦 ... Read More: https://lnkd.in/dPEWdN4g

NerPharMa, a veteran CDMO with a specialization in oncology small molecule drug manufacture and a member of NMS Group S.p.A, announced changes to the Board of Directors, following the shareholder resolution dated 13 May 2024. Claudio Salvagnini (Deputy CEO, NPM) and Tiziano LAZZARETTI (CFO, NMS Group), join Hugues Dolgos (Chairman and CEO, NPM & NMS Group) in NerPharMa Board of Directors.   This transition is part of NMS Group ongoing commitment to strong corporate governance and effective leadership.   We welcome the new members and are confident that their expertise will significantly benefit the Company. link: https://lnkd.in/dzc9syTM